1Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5 - fluorouracil (capecitabine, UFT, S-1): A review. Oncologist, 2002; 7 (4): 288 -323
2Hoff PM. the tegafur - based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin and S- 1: A review of their clinical development and therapeutic potential, Invest New Drugs, 2000; 18 (4) : 331 - 342
4Hirata K, Horikoshi N, Aiba K, et at. Pharmacokinetic study of S - 1, a novel oval fluorouracil antitumor drug. Clin Cancer Res, 1999; 5 (8) : 2000- 2005
5Aventis - Sanofi Group. S - 1 oral antlcancer agent improves patients' survival in adjuvant gastric cancer trial versus surgery alone (Press releases)o http:// en. sanofi-aventis.com/press/ppc-15653.asp (January 19, 2007)
6Maehara Y. S - 1 in gastric cancer: A comprehensive review. Gastric Cancer, 2003; 6 (Suppl 1) : 2- 8
7Nagashima F, Ohtsu A, Yoshida S, et al. Japanese nationwide post - marketing survey of S - 1 in patients with advanced gastric cancer. Gastric Cancer, 2005; 8 (1): 6-11
8Aventis - Sanofi Group. S - 1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S - 1 alone (Press releases) . http:// en. sanofi - aventis.com/press/ppc-16728.asp (June 3, 2007)
9Ohtsu A, Baba H, Sakata Y, et al. Phase Ⅱ study of S - 1, a novel oral fluoro- phyrimidine derivative, in patients with metastatic cotorectal carcinoma. Br J Cancer, 2(XX); 83 (2) : 141-145
10Jeung HC, Rha SY, Cho BC. et al. A phase Ⅱ trial of S - 1 monotherapy in metastatic cotorectal cancer after failure of irinotecan - and oxaliplatin - containing regimens. Br J Cancer, 2006; 95 (12): 1637-1641
